Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-Vbeta17/anti-CD123 bispecific antibody

A bispecific antibody, antigen technology, applied in the direction of antibody, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, anti-animal/human immunoglobulin, etc.

Pending Publication Date: 2021-12-31
JANSSEN BIOTECH INC
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are a number of potential complications with this approach to killing cancer cells, such as the selection of T cell antigens and cancer cell antigens that mediate T cell activation, selection in the case of bispecific antibodies that will have sufficient affinity to mediate Conjugated parental antibodies, and selection of cancer cell antigens that will activate T cells to act specifically against cancer cells rather than eliciting non-specific T cell activation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-Vbeta17/anti-CD123 bispecific antibody
  • Anti-Vbeta17/anti-CD123 bispecific antibody
  • Anti-Vbeta17/anti-CD123 bispecific antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0119] Embodiment 1 is an isolated Vβ17 bispecific antibody or antigen-binding fragment thereof, said isolated Vβ17 bispecific antibody or antigen-binding fragment thereof comprising:

[0120] a. The first heavy chain (HC1);

[0121] b. The second heavy chain (HC2);

[0122] c. the first light chain (LC1); and

[0123] d. The second light chain (LC2), wherein HC1 is associated with LC1 and HC2 is associated with LC2, and wherein HC1 comprises heavy chain complementarity determining region 1 (HCDR1), HCDR2 and HCDR3, which respectively comprise The amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and LC1 comprising light chain complementarity determining region 1 (LCDR1), LCDR2 and LCDR3 comprising SEQ ID NO: 4. The amino acid sequences of SEQ ID NO: 5 and SEQ ID NO: 6 to form the binding site for the first antigen, and wherein HC2 and LC2 form the binding site for the second antigen.

Embodiment approach 2

[0124] Embodiment 2 is the Vβ17 bispecific antibody or antigen-binding fragment thereof according to embodiment 1, wherein the binding site of the first antigen binds to Vβ17 on CD8+ T cells or CD4+ T cells.

Embodiment approach 3

[0125] Embodiment 3 is the Vβ17 bispecific antibody or antigen-binding fragment thereof according to embodiment 1 or 2, wherein said binding site of said second antigen binds to a tumor antigen present on the surface of a cancer cell.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Anti-Vbeta17 / anti-CD123 bispecific antibodies or antigen-binding fragments thereof are described herein. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application 62 / 816,464, filed March 11, 2019, the disclosure of which is incorporated herein by reference in its entirety. technical field [0003] The present invention relates to a monoclonal anti-Vβ17 / anti-CD123 bispecific antibody, a nucleic acid encoding the antibody, an expression vector, a recombinant cell containing the vector, and a composition containing the antibody. Also provided are methods of preparing the antibodies, and methods of using the antibodies to kill cancer cells. [0004] Reference Sequence Listing Submitted Electronically [0005] This application contains a Sequence Listing submitted electronically via EFS-Web as a Sequence Listing in ASCII format under the file name "PRD4012WOPCT Sequence Listing" with a creation date of March 11, 2020 and a size of 85kb. This Sequence Listing submitted via EFS-Web is part of this specification and is he...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/46C07K16/28C12N15/13A61K39/395A61P35/02
CPCC07K16/2809C07K16/2866A61P35/02C07K2317/31C07K2317/52C07K2317/73C07K2317/92C07K2317/565A61K2039/505
Inventor R·贾尼桑I·S·格雷瓦尔M·A·塞普尔维达
Owner JANSSEN BIOTECH INC